Nexletol, also known as bempedoic acid, is not expected to have a generic version available in 2026. The brand-name drug is currently protected by patents, which dictate when generic versions can enter the market [1].
When will Nexletol go generic?
The primary patent for Nexletol is set to expire in 2028 [1]. This date is critical for generic manufacturers, as it generally marks the earliest point they can seek approval and launch their products. However, patent landscapes can be complex, involving multiple patents with varying expiration dates, and patent litigation can extend or alter these timelines [1].
What is Nexletol used for?
Nexletol is a prescription medication used to lower LDL cholesterol in adults. It is prescribed for individuals with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who are already on a statin therapy but require additional LDL cholesterol reduction [2].
How does Nexletol work?
Nexletol functions by inhibiting an enzyme called ATP citrate lyase (ACL). This enzyme plays a role in the liver's production of cholesterol. By blocking ACL, Nexletol reduces the amount of cholesterol synthesized by the liver, which in turn helps to lower LDL cholesterol levels in the blood [2].
What are the side effects of Nexletol?
Common side effects reported with Nexletol include upper respiratory tract infections, muscle spasms, back pain, and increased levels of uric acid in the blood. Less common but more serious side effects can include hyperuricemia, tendon rupture, and muscle damage [2].
Can Nexlizet be taken with Nexletol?
Nexlizet is a combination medication that includes bempedoic acid (the active ingredient in Nexletol) and ezetimibe. They are often prescribed together to provide a more comprehensive approach to lowering LDL cholesterol [3].
Who makes Nexletol?
Nexletol is manufactured by Esperion Therapeutics [1].